SCHEMBL645001

SCHEMBL645001

O=S(=O)(O)c1ccccc1OC(F)(F)F

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALPL P05186 1/20 0.46
SLC22A12 Q96S37 4/20 0.45
SLC40A1 Q9NP59 1/20 0.45
PTGES2 Q9H7Z7 1/20 0.42
BRD4 O60885 1/20 0.41
HTR6 P50406 1/20 0.41
KDM2B Q8NHM5 1/20 0.40
ELANE P08246 1/20 0.40
GAA P10253 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RXRG P48443 1/20 0.40
AKR1C3 P42330 1/20 0.39
CHRM1 P11229 1/20 0.39
NAMPT P43490 2/20 0.39
ALDH1A1 P00352 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27729259 0.98 ALPL (0.45) ALPLSLC22A12SLC40A1PTGES2BRD4
Anthraquinone SCHEMBL28552724 0.92 BRD4 (0.46) ALPLSLC22A12SLC40A1PTGES2BRD4
SCHEMBL3528957 0.82 ELANE (0.60) ALPLSLC22A12SLC40A1PTGES2BRD4
SCHEMBL6972429 0.82 ALPL (0.47) ALPLSLC22A12SLC40A1PTGES2BRD4
SCHEMBL2646108 0.81 ALPL (0.46) ALPLSLC22A12SLC40A1PTGES2BRD4
SCHEMBL10646541 0.81 SLC22A12 (0.48) ALPLSLC22A12SLC40A1PTGES2BRD4
SCHEMBL29469931 0.81 PTGES2 (0.55) ALPLSLC22A12SLC40A1PTGES2HTR6
SCHEMBL122293 0.81 SLC22A12 (0.48) ALPLSLC22A12SLC40A1PTGES2BRD4
SCHEMBL692280 0.81 PTGES2 (0.55) ALPLSLC22A12SLC40A1PTGES2HTR6
SCHEMBL6039108 0.81 SLC22A12 (0.48) ALPLSLC22A12SLC40A1PTGES2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260008877-A1 HIGH MOLECULAR WEIGHT AND HIGHLY FUNCTIONAL VINYLIDENE FLUORIDE (VDF) BASED COPOLYMERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2026-01-08 US disclosed
EP-4536395-A1 CLAY COMPOSITE SUPPORT-ACTIVATORS AND CATALYST COMPOSITIONS Formosa Plastics Corporation, U.S.A. (US) 2025-04-16 EP disclosed
EP-4496819-A1 HIGH MOLECULAR WEIGHT AND HIGHLY FUNCTIONAL VINYLIDENE FLUORIDE (VDF) BASED COPOLYMERS Technion Research & Development Foundation Limited (IL) 2025-01-29 EP disclosed
CN-119278097-A Clay complex support-activator and catalyst composition 美国台塑公司 2025-01-07 CN disclosed
WO-2024221045-A1 IMMUNOGENIC COMPOSITION GRIFFITH UNIVERSITY (AU) 2024-10-31 WO disclosed
WO-2023239560-A1 CLAY COMPOSITE SUPPORT-ACTIVATORS AND CATALYST COMPOSITIONS FORMOSA PLASTICS CORPORATON, U.S.A. (US) 2023-12-14 WO disclosed
US-20230399420-A1 CLAY COMPOSITE SUPPORT-ACTIVATORS AND CATALYST COMPOSITIONS FORMOSA PLASTICS CORPORATION, U.S.A. (US) 2023-12-14 US disclosed
WO-2023181035-A1 HIGH MOLECULAR WEIGHT AND HIGHLY FUNCTIONAL VINYLIDENE FLUORIDE (VDF) BASED COPOLYMERS TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) 2023-09-28 WO disclosed
EP-3239190-B1 POLYMERIZATION CATALYSTS FOR PRODUCING POLYMERS WITH LOW LEVELS OF LONG CHAIN BRANCHING CHEVRON PHILLIPS CHEMICAL CO LP (US) 2020-01-29 EP disclosed
US-10365262-B2 Method of monitoring a parameter of a hydrocarbon well, pipeline or formation JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2019-07-30 US disclosed
CN-1436083-A Preparation of pathogen inactivated low immunogenic erythrocyte solution CERUS CORP (US) 2003-08-13 CN disclosed
WO-2003047650-A2 PREPARATION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY CERUS CORPORATION (US) 2003-06-12 WO disclosed
EP-1284743-A2 PREPARATION OF A PATHOGEN INACTIVATED SOLUTION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY Cerus Corporation (US) 2003-02-26 EP disclosed
US-20020042043-A1 Preparation of a pathogen inactivated solution of red blood cells having reduced immunogenicity STASSINOPOULOS ADONIS (US) 2002-04-11 US disclosed
WO-2001091775-A2 PREPARATION OF A PATHOGEN INACTIVATED SOLUTION OF RED BLOOD CELLS HAVING REDUCED IMMUNOGENICITY CERUS CORPORATION (US) 2001-12-06 WO disclosed
EP-0921817-B1 PEGYLATION PROCESS POLYMASC PHARMACEUTICALS PLC (GB) 2001-03-28 EP disclosed
EP-0921817-A1 PEGYLATION PROCESS PolyMASC Pharmaceuticals plc (GB) 1999-06-16 EP disclosed
EP-0906293-A1 SUBSTITUTED SULPHONYL AMINO(THIO)CARBONYL COMPOUNDS AND THEIR USE AS HERBICIDES BAYER AG (DE) 1999-04-07 EP disclosed
WO-1998032466-A1 PEGYLATION PROCESS POLYMASC PHARMACEUTICALS PLC (GB) 1998-07-30 WO disclosed
WO-1997046540-A1 SUBSTITUTED SULPHONYL AMINO(THIO)CARBONYL COMPOUNDS AND THEIR USE AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008877-A1 HIGH MOLECULAR WEIGHT AND HIGHLY FUNCTIONAL VINYLIDENE FLUORIDE (VDF) BASED COPOLYMERS MACF1, FIS1, PCNA ALPL 2450/4885SLC22A12 3578/4885SLC40A1 2890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.